Conversely, BET inhibition has demonstrated the potential to enhance anti-tumor immunity [50–52] by influencing the expression of immune-related genes [53], enhancing NK cell-mediated cytotoxicity [50], and improving responses to immune checkpoint therapy, both as a monotherapy [54] and in combination with other immunotherapeutic agents [55]. The gene discussed is DNER; the disease is neoplasm.